Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Single and Multiple Ascending Dose Study of TAS3731 in Healthy Adults
jRCT2031220505Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAS3731 (5 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Incidence of adverse events and adverse reactions, Vital signs and 2 more. Started Dec 2022; status: completed.
02
Drugs
TAS3731
Beyond the preview
Go deeper on jRCT2031220505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220505.